Weleda AG

Greenhouse gas emissions & sustainability report data

📊 Latest report period: 2023🗂️ Report periods on file: 2023

In its 2023 reporting, Weleda AG disclosed greenhouse gas emissions of 518.5K tCO2e (2022); Note: Significant changes in methodology and data quality make direct year-over-year comparisons difficult. 2023 data is pending.. By scope: Scope 1: 3.7K tCO2e (2023); Scope 2: 3.9K tCO2e (2023); Scope 3: 451.4K tCO2e (2023). Figures are as stated in the company's own report and may use different boundaries, units or methods (for example market-based vs location-based Scope 2), so compare with care.

💨
GHG Emissions
518.5K tCO2e (2022); Note: Significant changes in methodology and data quality make direct year-over-year comparisons difficult. 2023 data is pending.
2023
⚡
Renewable Energy
95% (for primary packaging in natural cosmetics)
of total energy
💧
Water Usage
226.9K m3 (2023)
2023
♻️
Waste
1.1K tons (2023)
2023
⚙️
Energy Use
31.6K MWh (2023)
2023

📊 Emissions by Scope (2023)

ScopeWhat it coversReported value
Scope 1Direct emissions from sources the company owns or controls (fuel combustion, company vehicles, process and fugitive emissions).3.7K tCO2e (2023)
Scope 2Indirect emissions from purchased electricity, steam, heat and cooling.3.9K tCO2e (2023)
Scope 3Other indirect emissions across the value chain (purchased goods, business travel, use of sold products, etc.).451.4K tCO2e (2023)

New to scopes? Read Scope 1, 2 and 3 emissions explained and market-based vs location-based Scope 2.

✅ Reported Environmental Achievements

🎯 Climate & Sustainability Targets

🔜 Short-term

  • Re-certification as a B Corp in 2024.

📅 Medium-term

  • Increase Rosmarin cultivation to 100 hectares by 2030.

🔭 Long-term

  • Achieve an emissions level compatible with the Paris Agreement's 1.5°C target by 2030 (implying net-zero emissions by 2050).

🌱 ESG Focus Areas

GovernanceCustomersWorkersCommunityEnvironment

⚠️ Challenges & Risks +

  • Increasing complexity of global raw material sourcing due to climate change and increased demand.
  • Loss of reimbursement for homeopathic and anthroposophic medicines in France leading to production activity cessation in Hüningen.
  • Negative results in the pharmaceuticals sector.

📋 Report Information

Reporting Period: 2023
Frameworks: GRI, B Corp
Assurance: PricewaterhouseCoopers AG